EMA/804585/2012

European Medicines Agency decision

P/0304/2012

of 20 December 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B Protein 936-741 / meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / recombinant Neisseria meningitis group B Protein 287-953 / recombinant Neisseria meningitis group B Protein 961c / meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein (MenABCWY) (EMEA-001260-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0304/2012

of 20 December 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B Protein 936-741 / meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / recombinant Neisseria meningitis group B Protein 287-953 / recombinant Neisseria meningitis group B Protein 961c / meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein (MenABCWY) (EMEA-001260-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Vaccines and Diagnostics S.r.l. on 9 March 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 November 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B Protein 936-741 / meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / recombinant Neisseria meningitis group B Protein 287-953 / recombinant Neisseria meningitis group B Protein 961c / meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein (MenABCWY), powder and suspension for suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B Protein 936-741 / meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / recombinant Neisseria meningitis group B Protein 287-953 / recombinant Neisseria meningitis group B Protein 961c / meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein (MenABCWY), powder and suspension for suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B Protein 936-741 / meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / recombinant Neisseria meningitis group B Protein 287-953 / recombinant Neisseria meningitis group B Protein 961c / meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein (MenABCWY), powder and suspension for suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina 1, 53100 - Siena, Italy.

Done at London, 20 December 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/555600/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001260-PIP01-11

Scope of the application

Active substance(s):

Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B Protein 936-741 / meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein / recombinant Neisseria meningitis group B Protein 287-953 / recombinant Neisseria meningitis group B Protein 961c / meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein (MenABCWY)

Condition(s):

Prevention of Meningococcal Meningitis

Pharmaceutical form(s):

Powder and suspension for suspension for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Novartis Vaccines and Diagnostics S.r.l.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novartis Vaccines and Diagnostics S.r.l. submitted for agreement to the European Medicines Agency on 9 March 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

The procedure started on 16 April 2012.

Supplementary information was provided by the applicant on 17 August 2012. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 9 November 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Prevention of Meningococcal Meningitis

The waiver applies to:

- Newborns and infants from birth to less than 2 months of age.
- for powder and suspension for suspension for injection, intramuscular use.
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: Prevention of Meningococcal Meningitis

2.1.1. Indication(s) targeted by the PIP

Active immunization against invasive disease caused by N. meningitides group A, B, C, Y, and W-135 of individuals from 2 months of age and older.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder and suspension for suspension for injection.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	2	Study 1: Intramuscular dose range-finding developmental toxicity study in rabbit (pilot study) Study 2: Pivotal reproductive and peri/post-natal developmental toxicity study in the rabbit
Clinical	11	Study 3: Observer-blind, controlled, randomized study to evaluate safety, tolerability and immunogenicity of four different rMenB plus Menveoformulations in healthy adolescents. Study 4: Observer-blind, controlled, randomized, extension study to evaluate safety, tolerability and immunogenicity of a third dose of one of four different formulations of rMenB + Menveo in adolescents who previously received the same study vaccines in study 3. Study 5: Observer-blind, controlled, randomized study in adolescents and

Area	Number of studies	Description
		young adults aged 10 to 25 years to evaluate safety and immunogenicity of two different rMenB with outer membrane vesicles (OMV) + Menveo formulations. Study 6: Partially-blind, controlled, randomized, extension study to evaluate the safety, and immunogenicity of administration of a single dose of two MenABCWY vaccine formulations 12 months after primary series to adolescents and young adults who completed study 5. Study 7: Randomized, observer-blind, controlled study to evaluate the lot-to-lot consistency of the MenABCWY vaccine, non-inferiority to single dose of Menveo, and sufficient immune response to B strains in adolescents. Study 8: Randomized, observer-blind, controlled, study to compare the safety and immunogenicity of two doses of Novartis MenABCWY Vaccine with one dose of Menveo in healthy vaccine-naive subjects at least 10 years of age. Study 9: Observer-blind, controlled, randomized study to evaluate the safety and immunogenicity of MenABCWY, when administered with Tetanus, Diphtheria toxoid, acellular Pertussis vaccine (Tdap, GlaxoSmithKline, Boostrix) and quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] recombinant vaccine (Merck & Co., Inc., Gardasil) in healthy adolescents. Study 10: Observer-blind, randomized, controlled study to evaluate safety and immunogenicity of four rMenB containing vaccine formulations in infants 2 months of age. Study 11: Observer-blind, randomized, controlled study to evaluate immunogenicity, reactogenicity and safety of the selected MenABCWY as compared to Menveo in healthy children aged 12 to less than 24 months. Study 12: Observer-blind, randomized, controlled study to evaluate immunogenicity, reactogenicity and safety of the selected MenABCWY as compared to Menveo in healthy children aged 2 to less than 10 years. Study 13: Observer-blind, randomized, controlled study to evaluate immunogenicity and safety of MenABCWY, when given to healthy infants at 2, 3, 4 and 12 months of age.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By December 2018.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.